about
Origin and therapy for hypertriglyceridaemia in type 2 diabetesAn online questionnaire survey of UK general practitioners’ knowledge and management of familial hypercholesterolaemiaNew data on familial hypercholesterolaemia and acute coronary syndromes: The promise of PCSK9 monoclonal antibodies in the light of recent clinical trials.Knowledge and Awareness of Familial Hypercholesterolaemia among Registered Medical Practitioners in Tamil Nadu: Are They Suboptimal?Postprandial hypertriglyceridemia and cardiovascular disease: current and future therapies.Critical review of non-statin treatments for dyslipoproteinemia.Can patients be accurately assessed for familial hypercholesterolaemia in primary care?Optimising the detection and management of familial hypercholesterolaemia: central role of primary care and its integration with specialist services.Pathogenesis and management of the diabetogenic effect of statins: a role for adiponectin and coenzyme Q10?Challenges in the care of familial hypercholesterolemia: a community care perspective.A new electronic screening tool for identifying risk of familial hypercholesterolaemia in general practice.International Developments in the Care of Familial Hypercholesterolemia: Where Now and Where to Next?Translational Research for Improving the Care of Familial Hypercholesterolemia: The "Ten Countries Study" and Beyond.A Web-Based Registry for Familial Hypercholesterolaemia.Increasing the Detection of Familial Hypercholesterolaemia Using General Practice Electronic Databases.Plasma Proprotein Convertase Subtilisin Kexin Type 9 as a Predictor of Carotid Atherosclerosis in Asymptomatic Adults.Frequency of familial hypercholesterolemia in patients with early-onset coronary artery disease admitted to a coronary care unit.Prevalence of Familial Hypercholesterolemia in Adolescents: Potential Value of Universal Screening?Effect of niacin on triglyceride-rich lipoprotein apolipoprotein B-48 kinetics in statin-treated patients with type 2 diabetes.Elevated lipoprotein(a), hypertension and renal insufficiency as predictors of coronary artery disease in patients with genetically confirmed heterozygous familial hypercholesterolemia.Design of the Familial Hypercholesterolaemia Australasia Network Registry: Creating Opportunities for Greater International Collaboration.Detection and management of familial hypercholesterolaemia in primary care in Australia: protocol for a pragmatic cluster intervention study with pre-post intervention comparisons.Familial hypercholesterolaemia in primary care: knowledge and practices among general practitioners in Western Australia.Angiographic progression of coronary atherosclerosis in patients with familial hypercholesterolaemia treated with non-statin therapy: Impact of a fat-modified diet and a resin.An enquiry based on a standardised questionnaire into knowledge, awareness and preferences concerning the care of familial hypercholesterolaemia among primary care physicians in the Asia-Pacific region: the "Ten Countries Study".Predicting Self-Management Behaviors in Familial Hypercholesterolemia Using an Integrated Theoretical Model: the Impact of Beliefs About Illnesses and Beliefs About Behaviors.Nutraceuticals in the management of patients with statin-associated muscle symptoms, with a note on real-world experience.Reverse cascade screening for familial hypercholesterolemia in high-risk Chinese families.A comparative analysis of phenotypic predictors of mutations in familial hypercholesterolemia.Effect of omega-3 fatty acid supplementation on arterial elasticity in patients with familial hypercholesterolaemia on statin therapy.ω-3 Fatty Acid Ethyl Esters Diminish Postprandial Lipemia in Familial Hypercholesterolemia.Effects of extended-release niacin on the postprandial metabolism of Lp(a) and ApoB-100-containing lipoproteins in statin-treated men with type 2 diabetes mellitus.Effectiveness of genetic cascade screening for familial hypercholesterolaemia using a centrally co-ordinated clinical service: an Australian experience.Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus.Plasma apolipoprotein B-48 transport in obese men: a new tracer kinetic study in the postprandial state.Cascade screening based on genetic testing is cost-effective: evidence for the implementation of models of care for familial hypercholesterolemia.Detecting familial hypercholesterolemia: The Jack and the Beanstalk principle.Familial combined hyperlipidemia and hyperlipoprotein(a) as phenotypic mimics of familial hypercholesterolemia: Frequencies, associations and predictions.Detecting familial hypercholesterolaemia in the community: impact of a telephone call from a chemical pathologist to the requesting general practitioner.Inter-relationships between proprotein convertase subtilisin/kexin type 9, apolipoprotein C-III and plasma apolipoprotein B-48 transport in obese subjects: a stable isotope study in the postprandial state.
P50
Q26824004-57DB7A86-0BE9-45A4-A11F-720DC1455548Q28591611-9A03E7E6-5CE4-454A-8618-613B859B3400Q36366067-12924E55-D4E1-4561-A6A7-42E33A6A3E1FQ37102772-29D47CAB-B626-419D-BC4B-FA6F12A80891Q38076370-E2091BA6-9400-4C04-9337-93E2214DE030Q38186099-E8C44302-306A-4DE6-BB6F-5E2644B5C6E7Q38234323-AAD7AEA2-CE87-44DE-BDBF-969724AE8611Q38240621-A49649C1-CA94-475B-B75B-C944CD6F58CFQ38268344-083E8481-84B5-4B52-83AD-53202032840AQ38575066-764B9C9D-CEE4-46A8-B95B-64FE55B92747Q38728768-BBE644A2-8D4B-454B-9508-79860EAA1536Q38745590-8BBCA906-ABC3-4586-9880-A42226751203Q38887927-F9F12B73-61AE-4FDB-8B99-07F1C58DCCAEQ39033426-78C95A20-E4B8-4626-BD17-9780B41D8989Q39152039-E9D99BEC-3345-4ECD-88E9-1EC488E832E9Q40169408-81CFFC26-58C5-45EA-8DC0-39E6D06B81D0Q40561209-70A1F92B-2523-499E-827A-70D26777DB26Q41031819-D8160F9F-3335-48AC-A5CB-00352E9B81BBQ41041086-18549EE0-6B14-4EA2-A44C-DE878A7D62A2Q41412379-50D0CFB6-FD3D-48A1-80FF-C5853BB26600Q42629536-47B5AB8A-535C-41B3-93A8-6BC056DC40BDQ42698475-AF1E044D-28E1-429F-B93D-178E721A91B9Q44268895-03564F6D-F94C-4B78-8C87-A11630614F10Q45020057-354771EF-F831-4AAD-AD6A-8E4203ADAD8FQ47161967-8E740FD2-AE45-4955-8960-C5B2F315D216Q47582310-B3F11329-288E-417E-9F3A-45F6267EA009Q48176908-E28F79FF-3F43-4ADC-974B-BE90197B0CBDQ48246564-017E631B-FDDB-4DAC-858B-B2182AAC96E5Q50161778-3C7F7EB3-0149-491C-8A5F-16896BA477F8Q50584948-98BA9460-4B9E-4135-96F2-190F09F9A1B2Q50599427-DD545122-2462-4ED6-9E38-AE62C044F556Q50783655-4C62CB6B-6528-45CF-8F5D-5FBE34B8707CQ51018059-C4B3AD73-C781-4EA0-966C-A12DF002F195Q51138000-96E9A912-0504-49EE-8228-44A5C84E9053Q51143783-C8135B9C-1E5F-49A6-B318-E44E1E2E995AQ51253022-30DE2A38-AA8F-4436-83C1-49C5EF5CEDA1Q51266244-93C6CB7D-FDB5-4F34-B5B2-1E8C2F07FDC3Q51284770-0A9075CE-8597-4399-90C6-010FDADEA40EQ53282069-8171AD36-D4C3-4888-9C43-642D2327C6B3Q54437683-FD08BFD9-6308-4A2A-B3C6-3DC92F51A976
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Jing Pang
@ast
Jing Pang
@en
Jing Pang
@es
Jing Pang
@nl
Jing Pang
@sl
type
label
Jing Pang
@ast
Jing Pang
@en
Jing Pang
@es
Jing Pang
@nl
Jing Pang
@sl
prefLabel
Jing Pang
@ast
Jing Pang
@en
Jing Pang
@es
Jing Pang
@nl
Jing Pang
@sl
P106
P31
P496
0000-0002-9700-6948